Defunct Company
Total Trials
9
As Lead Sponsor
5
As Collaborator
4
Total Enrollment
748
NCT00056550
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Phase: Phase 3
Role: Lead Sponsor
Start: Dec 31, 2002
Completion: Feb 29, 2004
NCT00110513
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
Start: Apr 30, 2005
Completion: Jul 31, 2008
NCT01158729
Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates
Phase: Phase 1
Role: Collaborator
Start: Aug 31, 2011
Completion: Dec 31, 2013
NCT01547728
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
Phase: Phase 4
Start: Feb 29, 2012
Completion: Feb 28, 2014
NCT01598883
"Understanding Heparin Resistance in Cardiac Surgery"
Start: Jun 30, 2012
Completion: Dec 31, 2014
NCT01708564
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
Start: Oct 31, 2012
Completion: Jun 30, 2013
NCT02020369
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
Start: Apr 30, 2014
Completion: Aug 31, 2015
NCT02059135
Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Start: Jul 11, 2014
Completion: Nov 30, 2016
NCT03090893
Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Phase: Early Phase 1
Start: Jun 1, 2018
Completion: Jun 30, 2019